Formulation & Evaluation of Entacapone Sustained Release Tablets
8 Angebote vergleichen
Preise | März 17 | Feb. 19 | Aug. 19 |
---|---|---|---|
Schnitt | Fr. 35.14 (€ 35.90)¹ | Fr. 33.84 (€ 34.58)¹ | Fr. 33.85 (€ 34.59)¹ |
Nachfrage |
1
Formulation & Evaluation of Entacapone Sustained Release Tablets
DE HC NW
ISBN: 9783659697463 bzw. 365969746X, in Deutsch, Lap Lambert Academic Publishing, gebundenes Buch, neu.
Lieferung aus: Deutschland, Versandkostenfrei innerhalb von Deutschland.
Parkinsonism is a progressive neuro degenerative illness which can be characterized by tremor, bradykinesia, rigidity, and postural instability. The effect of the Parkinsonism disease reaches 1-2% in people over the age of 50. The symptoms of Parkinsonism disease are largely related to progressive loss of dopamine in the basal ganglia. Parkinson´s disease can´t be cured, but medications can help control your symptoms, often dramatically. Entacapone is a Catechol-O-methyltransferase (COMT) Parkinsonism is a progressive neuro degenerative illness which can be characterized by tremor, bradykinesia, rigidity, and postural instability. The effect of the Parkinsonism disease reaches 1-2% in people over the age of 50. The symptoms of Parkinsonism disease are largely related to progressive loss of dopamine in the basal ganglia. Parkinson´s disease can´t be cured, but medications can help control your symptoms, often dramatically. Entacapone is a Catechol-O-methyltransferase (COMT) inhibitor which is the primary medication from this class. This medication when given in combination with levodopa, mildly prolongs the effect of levodopa therapy by blocking an enzyme that breaks down dopamine. The short half life of entacapone necessitated for fabricating entacapone sustained release matrix tablets to provide a therapeutic amount of drug and maintain the desired drug concentration. The objective of the present investigation was to develop Entacapone sustained release matrix tablets using various grades of HPMC K4M, K15M and K100M grades. Drug excipient compatibility of formulations was characterized by FTIR and DSC study and confirmed that no incompatibility was found. Lieferzeit 1-2 Werktage.
Parkinsonism is a progressive neuro degenerative illness which can be characterized by tremor, bradykinesia, rigidity, and postural instability. The effect of the Parkinsonism disease reaches 1-2% in people over the age of 50. The symptoms of Parkinsonism disease are largely related to progressive loss of dopamine in the basal ganglia. Parkinson´s disease can´t be cured, but medications can help control your symptoms, often dramatically. Entacapone is a Catechol-O-methyltransferase (COMT) Parkinsonism is a progressive neuro degenerative illness which can be characterized by tremor, bradykinesia, rigidity, and postural instability. The effect of the Parkinsonism disease reaches 1-2% in people over the age of 50. The symptoms of Parkinsonism disease are largely related to progressive loss of dopamine in the basal ganglia. Parkinson´s disease can´t be cured, but medications can help control your symptoms, often dramatically. Entacapone is a Catechol-O-methyltransferase (COMT) inhibitor which is the primary medication from this class. This medication when given in combination with levodopa, mildly prolongs the effect of levodopa therapy by blocking an enzyme that breaks down dopamine. The short half life of entacapone necessitated for fabricating entacapone sustained release matrix tablets to provide a therapeutic amount of drug and maintain the desired drug concentration. The objective of the present investigation was to develop Entacapone sustained release matrix tablets using various grades of HPMC K4M, K15M and K100M grades. Drug excipient compatibility of formulations was characterized by FTIR and DSC study and confirmed that no incompatibility was found. Lieferzeit 1-2 Werktage.
2
Formulation & Evaluation of Entacapone Sustained Release Tablets
DE NW
ISBN: 9783659697463 bzw. 365969746X, in Deutsch, neu.
Lieferung aus: Vereinigtes Königreich Grossbritannien und Nordirland, Lieferzeit: 11 Tage, zzgl. Versandkosten.
Parkinsonism is a progressive neuro degenerative illness which can be characterized by tremor, bradykinesia, rigidity, and postural instability. The effect of the Parkinsonism disease reaches 1-2% in people over the age of 50. The symptoms of Parkinsonism disease are largely related to progressive loss of dopamine in the basal ganglia. Parkinson's disease can't be cured, but medications can help control your symptoms, often dramatically. Entacapone is a Catechol-O-methyltransferase (COMT) inhibitor which is the primary medication from this class. This medication when given in combination with levodopa, mildly prolongs the effect of levodopa therapy by blocking an enzyme that breaks down dopamine. The short half life of entacapone necessitated for fabricating entacapone sustained release matrix tablets to provide a therapeutic amount of drug and maintain the desired drug concentration. The objective of the present investigation was to develop Entacapone sustained release matrix tablets using various grades of HPMC K4M, K15M and K100M grades. Drug excipient compatibility of formulations was characterized by FTIR and DSC study and confirmed that no incompatibility was found.
Parkinsonism is a progressive neuro degenerative illness which can be characterized by tremor, bradykinesia, rigidity, and postural instability. The effect of the Parkinsonism disease reaches 1-2% in people over the age of 50. The symptoms of Parkinsonism disease are largely related to progressive loss of dopamine in the basal ganglia. Parkinson's disease can't be cured, but medications can help control your symptoms, often dramatically. Entacapone is a Catechol-O-methyltransferase (COMT) inhibitor which is the primary medication from this class. This medication when given in combination with levodopa, mildly prolongs the effect of levodopa therapy by blocking an enzyme that breaks down dopamine. The short half life of entacapone necessitated for fabricating entacapone sustained release matrix tablets to provide a therapeutic amount of drug and maintain the desired drug concentration. The objective of the present investigation was to develop Entacapone sustained release matrix tablets using various grades of HPMC K4M, K15M and K100M grades. Drug excipient compatibility of formulations was characterized by FTIR and DSC study and confirmed that no incompatibility was found.
3
Formulation & Evaluation of Entacapone Sustained Release Tablets
DE PB NW
ISBN: 9783659697463 bzw. 365969746X, in Deutsch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
Formulation & Evaluation of Entacapone Sustained Release Tablets: Parkinsonism is a progressive neuro degenerative illness which can be characterized by tremor, bradykinesia, rigidity, and postural instability. The effect of the Parkinsonism disease reaches 1-2% in people over the age of 50. The symptoms of Parkinsonism disease are largely related to progressive loss of dopamine in the basal ganglia. Parkinson`s disease can`t be cured, but medications can help control your symptoms, often dramatically. Entacapone is a Catechol-O-methyltransferase (COMT) inhibitor which is the primary medication from this class. This medication when given in combination with levodopa, mildly prolongs the effect of levodopa therapy by blocking an enzyme that breaks down dopamine. The short half life of entacapone necessitated for fabricating entacapone sustained release matrix tablets to provide a therapeutic amount of drug and maintain the desired drug concentration. The objective of the present investigation was to develop Entacapone sustained release matrix tablets using various grades of HPMC K4M, K15M and K100M grades. Drug excipient compatibility of formulations was characterized by FTIR and DSC study and confirmed that no incompatibility was found. Englisch, Taschenbuch.
Formulation & Evaluation of Entacapone Sustained Release Tablets: Parkinsonism is a progressive neuro degenerative illness which can be characterized by tremor, bradykinesia, rigidity, and postural instability. The effect of the Parkinsonism disease reaches 1-2% in people over the age of 50. The symptoms of Parkinsonism disease are largely related to progressive loss of dopamine in the basal ganglia. Parkinson`s disease can`t be cured, but medications can help control your symptoms, often dramatically. Entacapone is a Catechol-O-methyltransferase (COMT) inhibitor which is the primary medication from this class. This medication when given in combination with levodopa, mildly prolongs the effect of levodopa therapy by blocking an enzyme that breaks down dopamine. The short half life of entacapone necessitated for fabricating entacapone sustained release matrix tablets to provide a therapeutic amount of drug and maintain the desired drug concentration. The objective of the present investigation was to develop Entacapone sustained release matrix tablets using various grades of HPMC K4M, K15M and K100M grades. Drug excipient compatibility of formulations was characterized by FTIR and DSC study and confirmed that no incompatibility was found. Englisch, Taschenbuch.
4
Formulation & Evaluation of Entacapone Sustained Release Tablets
DE PB NW
ISBN: 365969746X bzw. 9783659697463, in Deutsch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
5
Formulation & Evaluation of Entacapone Sustained Release Tablets
~EN PB NW
ISBN: 365969746X bzw. 9783659697463, vermutlich in Englisch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
6
Formulation & Evaluation o (2017)
DE PB NW
ISBN: 9783659697463 bzw. 365969746X, in Deutsch, Taschenbuch, neu.
Lieferung aus: Deutschland, Next Day, Versandkostenfrei.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…